title: [Clinical efficacy of combined anti-Helicobacter treatment of patients with duodenal ulcer].
abstract: 84 patients with duodenal ulcer and positive by Helicobacter pylori (HP) were divided into two groups. Group 1 consisted of 42 patients who received omeprasol, metranidasol and clarithromycin. Group 2 of 42 patients received rovamycin instead of clarythromycin. The results of the study show that anti-HP regimen with rovamycin is superior to clarythromycin by main criteria (percent of healed ulcers, HP eradication, time to remission, recurrence rate, side effects rate). Thus, three-component therapy of patients with recurrent duodenal ulcer maintains intragastric acidity optimal for fast healing of ulcer defect.
authors.forename: N V
authors.initials: NV
authors.lastname: Kirika
authors.forename: N I
authors.initials: NI
authors.lastname: Bodrug
authors.forename: S I
authors.initials: SI
authors.lastname: Butorov
authors.forename: O N
authors.initials: ON
authors.lastname: Verbitskiĭ
authors.forename: A Iu
authors.initials: AIu
authors.lastname: Ridlovskiĭ
authors.forename: I V
authors.initials: IV
authors.lastname: Butorov
authors.forename: D I
authors.initials: DI
authors.lastname: Lagutkin
authors.forename: L I
authors.initials: LI
authors.lastname: Martyniuk
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D017291:Clarithromycin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004381:Duodenal Ulcer / Q000188:drug therapy* / Q000382:microbiology*; D005260:Female; D016480:Helicobacter pylori / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000627:therapeutic use; D015572:Spiramycin / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D015572:Spiramycin; D017291:Clarithromycin; D009853:Omeprazole